Generally, fighting cancer is about delivering a relentless attack on the spreading disease, but a new approach explores the ...

On track for first Biologics License Application (BLA) approved cell therapy in unaddressed orphan indication – – NEXICART-2 interim results were presented at ASCO 2025 – LOS ANGELES, CA, July 07, ...

Research by Weizmann Institute scientist and Israel Prize winner saved 'countless lives,' was basis for technology sold for ...

A novel chimeric antigen receptor T-cell therapy may benefit patients with B-cell lymphomas who previously relapsed following ...

While data is promising, many questions remain about topics such as timing and doses in the treatment of hematologic malignancies.

A team of physicians recently reported the successful treatment of refractory autoimmune neuropathies through the infusion of ...

During a live event, Priyanka Pophali, MD, MBBS, discussed CAR T-cell therapy referrals, timing, and challenges in relapsed ...

A team of researchers led by NYU Tandon School of Engineering's Weiqiang Chen has developed a miniature device that could ...

A Martin County family with a child fighting rare cancer is getting help from the community to get treatment abroad.

From FDA approvals streamlining access to critical therapies to new breakthroughs in challenging malignancies, the field of cancer care continues to demonstrate remarkable progress.

Previously, due to the risk of cytokine release syndrome and neurological toxicities, many CAR T-cell therapies included a REMS requirement.

Thermo Fisher Scientific Inc. (NYSE:TMO) ranks among the best CRISPR stocks to buy. On June 24, Thermo Fisher Scientific Inc.